Report Finds High Costs For Pay-For-Delay Drugs

Law360, New York (July 16, 2013, 6:30 PM EDT) -- Reverse payment patent settlements have left U.S. consumers paying on average 10 times more for brand-name versions of key drugs used to treat everything from breast cancer to high cholesterol while waiting for generics to enter the market, according to a study released Thursday.

On average, so-called pay-for-delay settlements have held up the market entry of generic versions of blockbuster drugs for five years, according to a report published Thursday by public interest groups Community Catalyst and U.S. Public Interest Research Group.

The study is based...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.